INmune Bio, Inc.
INMB
$1.63
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 50.00K | 50.00K | 50.00K | 14.00K | 42.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.00K | 50.00K | 50.00K | 14.00K | 42.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 50.00K | 50.00K | 50.00K | 14.00K | 42.00K |
| SG&A Expenses | 9.36M | 8.94M | 9.50M | 9.52M | 9.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.91M | 39.77M | 41.57M | 42.65M | 41.59M |
| Operating Income | -34.86M | -39.72M | -41.52M | -42.64M | -41.55M |
| Income Before Tax | -49.89M | -55.51M | -40.80M | -42.08M | -41.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.89 | -55.51 | -40.80 | -42.08 | -41.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.89M | -55.51M | -40.80M | -42.08M | -41.27M |
| EBIT | -34.86M | -39.72M | -41.52M | -42.64M | -41.55M |
| EBITDA | -7.42M | -- | -- | -- | -- |
| EPS Basic | -2.14 | -2.50 | -1.95 | -2.13 | -2.18 |
| Normalized Basic EPS | -0.91 | -1.12 | -1.22 | -1.33 | -1.36 |
| EPS Diluted | -2.14 | -2.50 | -1.95 | -2.13 | -2.18 |
| Normalized Diluted EPS | -0.91 | -1.12 | -1.22 | -1.33 | -1.36 |
| Average Basic Shares Outstanding | 94.63M | 88.23M | 84.24M | 79.77M | 75.54M |
| Average Diluted Shares Outstanding | 94.63M | 88.23M | 84.24M | 79.77M | 75.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |